Boston life insurance company John Hancock announced it is providing free access to Galleri cancer screening tests to special ...

AT&T, T-Mobile, and Verizon offer free trials with eSIM, so you can see if the network is a good fit where you live without ...

Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...

Detailed price information for Exact Sciences Cor (EXAS-Q) from The Globe and Mail including charting and trades.

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue-based ...

Exact Sciences Corp ( (EXAS) ) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its ...

The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million.

Hello. At this time, I would like to welcome everyone to the Exact Sciences. Third quarter, 2024 earnings conference call. (Operator Instructions) I would now like to turn the call over to Erik ...

At this time, I would like to welcome everyone to the Exact Sciences third-quarter 2024 earnings conference call. [Operator ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...

It may be tempting to throw away COVID-19 home test kits that are near their expiration dates, but the FDA is encouraging ...

Please verify your email address. Your browser does not support the video tag. Free-to-play games come in many shapes and sizes. Battle royales and hero shooters are ...